Zio vs SimpleSense

A cardiology practice can weigh these two together, since each sells remote cardiac monitoring. Zio from iRhythm is an ECG patch with cloud analysis, technician review and a physician report, backed by 18 FDA decisions, the Zio monitor on August 15, 2025 among them, and an FDA warning letter dated May 25, 2023.

Nanowear's SimpleSense is a cloth garment that the vendor describes as a home-based platform for cardiometabolic assessment, including heart failure monitoring. Its four 510(k) decisions run from SimplECG in 2016 to SimpleSense-BP, for cuffless blood pressure, on December 8, 2023. A 2025 prospective multicentre study of 303 subjects by Nanowear authors was an internal validation, and the authors ask for external validation. Funding figures conflict: Tracxn lists USD 1.52M over two rounds, ZoomInfo says under USD 5M in two rounds with the last closing April 29, 2020, and MobiHealthNews reported USD 1.5M in September 2014.

For a practice ordering ambulatory arrhythmia monitoring, Nanowear trails iRhythm, because Zio is described as arrhythmia detection with a physician report and SimpleSense as cardiometabolic assessment. A heart failure program wanting garment-based readings at home fits Nanowear.